FDA IND approval for Zn-DTPA, new clinical agent for decorporation therapy of actinides.
D008671:Actinoid Series Elements / Q000009:adverse effects* / Q000378:metabolism; D002986:Clinical Trials as Topic; D006801:Humans; D004369:Pentetic Acid / Q000627:therapeutic use*; D011005:Plutonium / Q000378:metabolism; D015032:Zinc / Q000627:therapeutic use*
D008671:Actinoid Series Elements; D011005:Plutonium; D004369:Pentetic Acid; D015032:Zinc